Clinical Trial Update: A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating XEN1101 as adjunctive therapy in focal epilepsy has posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Epilepsy

Drugs mentioned

• XEN1101

Snippet

Sponsor: Xenon Pharmaceuticals Inc. | Conditions: Focal Epilepsy | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-09-24